The global burden of CHD is believed to be relatively constant with 0.9 percent of children being born with CHD.
An Overview of Rosuvastatin/Ezetimibe Association for the Treatment of Hypercholesterolemia and Mixed Dyslipidemia
Elevated serum level of low-density lipoprotein cholesterol (LDL-C) is highly correlated with an enhanced risk to arise coronary artery disease and other atherosclerosis-related diseases.
Diabetes adults are at an increased risk of fracturing a bone as compared to the general adults.
Low-Density Lipoproteins Cause Atherosclerotic Cardiovascular Disease: Pathophysiological, Genetic, and Therapeutic Insights: A Consensus Statement from the European Atherosclerosis Society Consensus Panel
Non-invasive imaging in the PESA (Progression of Early Subclinical Atherosclerosis) study revealed that 71% and 43% of middle-aged men and women, respectively, have evidence of subclinical atherosclerosis.
Inflammatory Cell Infiltration in Left Atrial Appendageal Tissues of Patients with Atrial Fibrillation and Sinus Rhythm
The prime states susceptible to atrial fibrillation (AF) are aging, arterial hypertension, coronary artery disease, congestive heart failure and valvular heart disease.
According to a 2-year study, in chronic musculoskeletal pain patients, an enhancement in opioid dosage seems to be of no precise benefit.
Impact of Diabetes on Clinical Outcome of Patients with Heart Failure Undergoing ICD and CRT Procedures: Results from the German Device Registry
Diabetes mellitus (DM) has a negative impact on prognosis in patients with heart failure (HF).
FURIN Expression in Vascular Endothelial Cells Is Modulated by a Coronary Artery Disease Associated Genetic Variant and Influences Monocyte Transendothelial Migration
A coronary artery disease (CAD) responsiveness is focused on chromosome 15q26.1, recognized by genome-wide association studies.
As reported by a new research from the American Medical Association (AMA), 43.9% of physician surveyed, notified at least one symptom of burnout and as compared with other working adults in the United States were at a high risk for burnout.
American Diabetes Association 79th Scientific Sessions, San Francisco, California, June 07th – 11th, 2019 (ADA 2019)
The 79th American Diabetes Association (ADA) Scientific Sessions was held in San Francisco, LA from June 7 to 11th, 2019. Some breakthrough results were presented at the 79th ADA including news and expert commentaries on the CAROLINA, REWIND, PIONEER trial. Carbon Brand Solutions feels privileged to witness the revelation of the much-awaited results and findings of these breakthrough trials and was fortunate to gain insights from the leading experts in the field of diabetes.